非小细胞肺癌仍然在晚期诊断，并且需要系统治疗。当前我们有三种主要的治疗方式，化疗、靶向酪氨酸激酶抑制剂和免疫检查点抑制剂。根据最新研究，在最近几年中，我们可以使用化疗和免疫疗法的联合治疗，或者放疗和免疫疗法的联合治疗。每种治疗方法都基于肿瘤的特定基因表达。酪氨酸激酶抑制剂已经用于表皮生长因子阳性肿瘤超过十年，与间变淋巴瘤激酶和原癌基因1一样。已经发现，程序化死亡配体1的表达与免疫检查点抑制剂的疗效相关。然而，非小细胞肺癌患者中仍然存在若干亚群。我们将根据最新的研究，对KRAS G12C突变亚群及其与sotorasib的靶向治疗的疗效和毒性进行评论。版权所有 © 2023。由Elsevier Ltd.出版。

Non-small cell lung cancer is still diagnosed at a late disease stage and systematic therapy is necessary. Currently we have three main treatment modalities; chemotherapy, targeted with tyrosine kinase inhibitors and immune check point inhibitors. In the recent years and based on new studies we can administer combination of chemotherapy and immunotherapy, or radiotherapy and immunotherapy. Every treatment approach is based on the specific gene expression of the tumor. Tyrosine kinase inhibitors have been used for more than a decade for epidermal growth factor positive tumors, the same for anaplastic lymphoma kinase and proto-oncogene 1. Programmed death-ligand 1 expression has been found to be associated with the efficiency of immune checkpoint inhibitors. However; there are still several subpopulations in non-small cell lung cancer patients. We will comment on the group with KRAS G12C mutation and the targeted therapy with sotorasib for its efficiency and toxicity based on new studies.Copyright © 2023. Published by Elsevier Ltd.